FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · The US Food and Drug Administration approved the first vaccine against respiratory syncytial virus, known as RSV, and vaccines are in the works.
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of...
FDA approves RSV vaccine for adults ages 60 and up - NBC News
WEBMay 3, 2023 · Researchers first attempted to develop a vaccine for respiratory syncytial virus roughly 60 years ago. In a late-stage clinical trial, the single-dose shot lowered the risk of symptomatic illness...
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
WEBMay 31, 2024 · mRESVIA (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.
Should You Get the New RSV Vaccine? > News > Yale Medicine
WEBSep 25, 2023 · Respiratory syncytial virus (RSV) causes mild cold symptoms in most people but can lead to hospitalization and even death in older people and babies. But now, there are new immunizations aimed at older people, babies, and pregnant women who want to protect their newborns.
CDC Updates RSV Vaccination Recommendation for Adults
WEBJun 26, 2024 · Today, CDC updated its recommendation for the use of Respiratory Syncytial Virus (RSV) vaccines in people ages 60 and older. For this upcoming respiratory virus season, CDC recommends: Everyone …
‘A good day’: FDA approves world’s first RSV vaccine - Nature
WEBMay 3, 2023 · The US Food and Drug Administration (FDA) has approved GSK’s vaccine against respiratory syncytial virus (RSV) for use in people aged 60 years and older. This is the first RSV vaccine to gain...
FDA Approves New Drug to Prevent RSV in Babies and Toddlers
WEBToday, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and...
Progress at last against RSV - Nature Medicine
WEBSep 14, 2023 · A surge in respiratory syncytial virus (RSV) infections and RSV-related hospitalizations in the 2023 Southern Hemisphere winter, similar to that seen in 2022 in northern climes, has strained...
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ...
WEBApr 9, 2024 · ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk. The vaccine was well-tolerated and demonstrated an immune response non-inferior to adults aged 60 years and older